Consumers seem to be turning to hemp and cannabis products during the current crisis, which has buoyed the near term outlook for Curaleaf, one of the largest companies in the sector, which posted strong revenue growth in its recent annual report.
An analysis of recent warning letters underscores the notion that FDA is focused its enforcement efforts on CBD, and is not targeting hemp extracts per se.
